GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (OTCPK:SHTDY) » Definitions » Pretax Margin %

SHTDY (Sinopharm Group Co) Pretax Margin % : 2.58% (As of Jun. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Sinopharm Group Co Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Sinopharm Group Co's Pre-Tax Income for the six months ended in Jun. 2024 was $1,047 Mil. Sinopharm Group Co's Revenue for the six months ended in Jun. 2024 was $40,626 Mil. Therefore, Sinopharm Group Co's pretax margin for the quarter that ended in Jun. 2024 was 2.58%.

The historical rank and industry rank for Sinopharm Group Co's Pretax Margin % or its related term are showing as below:

SHTDY' s Pretax Margin % Range Over the Past 10 Years
Min: 2.4   Med: 3.32   Max: 3.65
Current: 2.4


SHTDY's Pretax Margin % is ranked worse than
50.89% of 112 companies
in the Medical Distribution industry
Industry Median: 2.415 vs SHTDY: 2.40

Sinopharm Group Co Pretax Margin % Historical Data

The historical data trend for Sinopharm Group Co's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Pretax Margin % Chart

Sinopharm Group Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.42 3.26 3.36 3.27 2.40

Sinopharm Group Co Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.63 2.95 3.60 2.58 2.21

Competitive Comparison of Sinopharm Group Co's Pretax Margin %

For the Medical Distribution subindustry, Sinopharm Group Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinopharm Group Co's Pretax Margin % Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's Pretax Margin % falls into.


;
;

Sinopharm Group Co Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Sinopharm Group Co's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=2732.716/83550.82
=3.27 %

Sinopharm Group Co's Pretax Margin for the quarter that ended in Jun. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=1047.113/40625.637
=2.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinopharm Group Co  (OTCPK:SHTDY) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Sinopharm Group Co Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinopharm Group Co Business Description

Traded in Other Exchanges
Address
No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2023. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Sinopharm Group Co Headlines

From GuruFocus

Sinopharm Group Co Ltd's Dividend Analysis

By GuruFocus Research 06-17-2024

Matthews China Fund 1st Quarter Commentary

By Holly LaFon Holly LaFon 05-19-2016

Matthews China Fund Q3 2014 Commentary

By Holly LaFon Holly LaFon 10-18-2014

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 07-30-2020

Matthews China Fund Comments on Sinopharm Group

By Vera Yuan Vera Yuan 10-20-2014

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 01-25-2021

Matthews China Fund Comments on Sinopharm

By Holly LaFon Holly LaFon 05-19-2016